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Objectives: After portosystemic anastomoses for biliopathy, some patients continue to suffer biliary
obstruction. The effects of splenectomy and devascularization of the abdominal oesophagus and upper
stomach are unclear. The aim of the current study was to determine the features of portal biliopathy (PB)
in patients with non-cirrhotic portal hypertension, and to investigate outcomes in these patients after
surgical procedures.
Methods: A retrospective study of 56 patients who underwent surgery for PB during 1996–2010 was
conducted. Data on presenting features, treatment received and outcomes were analysed.
Results: In total, 41 of these patients had extrahepatic portal venous obstruction and 15 had non-
cirrhotic portal fibrosis. Forty patients underwent shunt surgery and 16 underwent splenectomy and
devascularization. Median bilirubin levels fell from 1.8 mg/dl (range: 0.4–5.9 mg/dl) to 1.0 mg/dl (range:
0.3–5.4 mg/dl) after shunt surgery and from 1.9 mg/dl (range: 0.6–4.0 mg/dl) to 1.2 mg/dl (range: 0.6–
5.2 mg/dl) after splenectomy–devascularization. On follow-up, five of 33 patients had persistent jaundice
after successful shunt surgery. These patients had a history of multiple endoscopic stentings and three
patients had demonstrated a dominant common bile duct stricture preoperatively.
Conclusions: Portal biliopathy was reversed in 38 of 43 patients by either portosystemic shunting or
splenectomy–devascularization. In five patients, direct biliary decompressive procedures were required
because of shunt blockage or a non-reversible biliary stricture.
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Introduction
Although changes in the biliary tract in patients with portal
hypertension were first described as early as 1944,1 the term ‘portal
biliopathy’ was not coined until the early 1990s, when it was used
to define structural changes in the extra- or intrahepatic bile ducts
secondary to portal hypertension.2 Portal biliopathy (PB) is most
commonly seen in extrahepatic portal venous obstruction
(EHPVO), in which it has been reported to occur in 80–100% of
patients, although it is asymptomatic in the majority.3,4 The con-
dition has also been described in non-cirrhotic portal fibrosis
(NCPF) and cirrhosis, albeit in smaller proportions of patients.5
Symptomatic PB is often managed by endoscopic stent insertion
into the common bile duct (CBD). Choudhuri et al.6 first
described a patient in whom a portosystemic shunt procedure was
effective in reversing the radiological and biochemical biliary
changes in symptomatic PB. Later, Chaudhary et al.7 described
seven patients with PB who underwent portal decompression.
This paper is based on an oral presentation given at the Annual Conference
of the International Hepato-Pancreato-Biliary Association, Indian Chapter,
19–21 November 2010, New Delhi.
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However, two of these patients, despite having patent anasto-
moses, continued to require postoperative endoscopic stenting,
indicating that effective portal decompression does not always
reverse PB.
Several questions regarding the management of PB remain
unanswered, including those concerning how to identify patients
who will benefit from surgical intervention, the optimal operation
(shunt surgery, devascularization procedures, splenectomy),
and the percentage of patients who will require subsequent
decompression of the biliary tree.
The aim of the current investigation was to evaluate the
presenting features of PB in patients with non-cirrhotic portal
hypertension (EHPVO and NCPF) who underwent surgical inter-
ventions (both shunt and non-shunt procedures) and to study
short- and longterm outcomes in these patients.
Materials and methods
A retrospective review of data from a prospectively maintained
database was performed. All patients who underwent surgical
interventions for non-cirrhotic hypertension (EHPVO and
NCPF) between 1996 and 2010 and who had symptomatic, bio-
chemical or radiological findings suggestive of PB were identified
and selected for analysis. Patients with cirrhosis of the liver were
excluded from the study.
Preoperative data collected included the demographic profile of
the patients, their presenting complaints, indications for surgery,
preoperative endoscopic treatment details, and preoperative labo-
ratory investigations. Perioperative details included the type of
surgery, intraoperative findings and immediate, early and delayed
laboratory values. Postoperative follow-up details included the
incidence of recurrent bleeding, recurrence or appearance of
symptoms of biliary obstruction, endoscopic interventions, the
presence or absence of signs of progressive end-stage liver disease,
development of cholelithiasis or choledocholithiasis, requirement
for bilioenteric bypass or cholecystectomy, as well as data on
quality of life as indicated by return to work, presence or absence
of symptoms of biliary obstruction, relief from frequent hospital
visits and the level of general well-being of the patient. Follow-up
was conducted by studying outpatient visits or by telephone and
written communication.
Extrahepatic portal venous obstruction was defined as the
obstruction of the extrahepatic portal vein with or without
involvement of the intrahepatic portal veins. It did not include
isolated thrombosis of the splenic vein or superior mesenteric vein
(SMV). This form of hypertension is characterized by features of
portal hypertension with a portal cavernoma.8
Non-cirrhotic portal fibrosis was defined as a disease of uncer-
tain aetiology characterized by a normally functioning liver, a
large spleen and a dilated unobstructed portal venous system. The
liver biopsy often shows periportal fibrosis and thromboses in the
small and medium branches of the portal vein.9
Portal biliopathy was defined in the current study as indicated
by an elevation of total bilirubin to >1.5 mg/dl with a predomi-
nant increase in direct bilirubin and/or elevated serum alkaline
phosphatase (SAP) (>125 IU/ml), or according to evidence on
computed tomography (CT) or magnetic resonance imaging
(MRI) of dilatation of extra- or intrahepatic biliary radicals, single
or multiple strictures, CBD stones or a beaded appearance of the
CBD.
Portal biliopathy was categorized as symptomatic when the
patient’s presenting complaints included jaundice, pruritus, pain,
fever or a history of single or multiple endoscopic retrograde
cholangiopancreatography (ERCP) with or without stenting. It
was considered to be asymptomatic if the biochemical and/or
imaging findings were suggestive of the bile duct abnormalities
described earlier and the patient had no symptoms of biliary
obstruction. Endoscopic retrograde cholangiopancreatography
was performed only in symptomatic patients with features of
cholangitis or bile duct stones.
Resolution of PB was defined in symptomatic patients as relief
from symptoms of biliary obstruction and in asymptomatic
patients as a significant decrease in bilirubin and SAP levels or a
reversal of radiological signs of biliary obstruction. Failure of a
surgical intervention was defined as an inability to achieve reso-
lution of PB.
The preferred surgical intervention was a portosystemic shunt
procedure. The choice of shunt surgery was based on the sur-
geon’s preference, the presence or absence of massive splenom-
egaly with hypersplenism, a previous history of splenectomy
or shunt surgery, and the presence of a suitable shuntable vein.
A splenectomy–devascularization procedure was performed if
there was no suitable shuntable vein or if there was a massive
bleed. A cholecystectomy was performed along with a shunt or
splenectomy–devascularization procedure if gallstones were seen
on preoperative imaging and in the absence of significant gall-
bladder varices. A cholecystojejunostomy or a choledochojejun-
ostomy was performed in patients in whom ERCP was not feasible
or had failed to relieve biliary obstruction.
Statistical analysis was performed usingWilcoxon’s signed rank
test. A P-value of <0.05 was considered to indicate statistical sig-
nificance. Analysis was conducted using spss Version 16.0 (SPSS,
Inc., Chicago, IL, USA).
Results
During the study period of 14 years, a total of 113 patients with
EHPVO and 42 patients with NCPF underwent surgery in the
department. The median ages of patients without PB but with
EHPVO or NCPF were 18 years (range: 4–57 years) and 33 years
(range: 20–61 years), respectively. Recurrent upper gastrointesti-
nal (GI) bleed was the most common indication for surgery and
was seen in 61 of 113 (54.0%) and 17 of 42 (40.5%) patients with
EHPVO and NCPF, respectively.
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Clinical profile of PB
A total of 41 patients with EHPVO and 15 patients with NCPF
were found to have PB; these represent the current study group
of 56 patients (36.1%). The group included 39 male and 17 female
patients with a median age of 26 years (range: 3–68 years).
The median ages of patients in the EHPVO-PB and NCPF-PB
groups were 23 years (range: 3–50 years) and 34 years (range:
20–68 years), respectively.
Symptomatic PB was seen in 24 of 56 (42.9%) patients. The
median age of patients with symptomatic PB was 26 years (range:
13–68 years). Of these patients, 12 had undergone ERCP prior to
operation. The median number of ERCPs per patient was 2.5
(range: 1–5); a total of 32 procedures had been performed. Two
patients underwent ERCP with nasobiliary drainage and the rest
underwent ERCP with stenting. Twelve patients had features of
biliary obstruction with recurrent upper GI bleeding or hyper-
splenism and underwent surgery without prior endoscopic inter-
vention. Jaundice, pruritus, cholangitis requiring ERCP and
drainage were the chief indications for surgery in 13 of 24
patients, whereas recurrent upper GI bleed, lower GI bleed and
hypersplenism were the chief indications for surgery in 11 of 24
patients with symptomatic PB.
A total of 32 (57.1%) patients had asymptomatic PB. The
median age of this group of patients was 27 years (range:
3–61 years). Of these, six patients had only abnormalities on
imaging (CT, MRI, magnetic resonance cholangiopancreatogra-
phy) and 26 had altered liver function tests. Clinical features are
given in detail in Table 1.
Imaging characteristics
Details of imaging characteristics are shown in Table 2. In patients
with EHPVO, dilatation of intrahepatic biliary radicals was the
most common finding (Figs 1 and 2). Three NCPF patients had
evidence of nodular liver with ascites. However, cirrhosis was
ruled out on liver biopsy.
Operations
Portosystemic shunt surgery was the most common procedure in
the EHPVO-PB group, whereas shunt and non-shunt surgeries
were performed almost equally in the NCPF-PB group. One
Table 1 Clinical features of patients with portal biliopathy (PB)
Finding EHPVO-PB
(n = 41), n
NCPF-PB
(n = 15), n
Total (n = 56),
n (%)
Upper GI bleeding 26 8 34 (60.7)
Jaundice 21 3 24 (42.8)
Cholangitis 7 0 7 (12.5)
Abdominal pain 6 6 12 (21.4)
Melaena 5 2 7 (12.5)
Abdominal lump 5 2 7 (12.5)
Hypersplenism 4 4 8 (14.3)
Growth failure 2 0 2 (3.5)
Pruritus 2 0 2 (3.5)
Haemobilia 1 0 1 (1.7)
Ascites 0 3 3 (5.4)
EHPVO, extrahepatic portal venous obstruction; NCPF, non-cirrhotic
portal fibrosis; GI, gastrointestinal.
Table 2 Imaging characteristics of patients with portal biliopathy
(PB)
Imaging characteristic EHPVO-PB
(n = 27), n
NCPF-PB
(n = 6), n
Total
(n = 33),
n
Intrahepatic bile duct dilatation 13 1 14
Bile duct stricture 3 0 3
Gallbladder stones 9 2 11
Common bile duct stones 6 1 7
Multiple strictures
(pseudosclerosing
cholangitis)
5 0 5
Extrahepatic biliary dilatation
alone
3 0 3
Left hepatic duct dilatation
alone
1 0 1
Nodular liver 0 3 3
EHPVO, extrahepatic portal venous obstruction; NCPF, non-cirrhotic
portal fibrosis.
Figure 1 Endoscopic retrograde cholangiopancreatography show-
ing dilatation of the intrahepatic biliary radicals with beaded
appearance of the common bile duct
HPB 443
HPB 2012, 14, 441–447 © 2012 International Hepato-Pancreato-Biliary Association
patient in the NCPF group underwent a choledochojejunostomy
along with the shunt procedure (Table 3).
Laboratory investigations
Median preoperative bilirubin in the study group was 1.8 mg/dl
(range: 0.4–5.9 mg/dl). Median SAP was 138 IU/ml (range:
23–765 IU/ml). After surgery (including shunt and non-shunt
procedures), median bilirubin and SAP were 1.2 mg/dl (range:
0.3–5.4 mg/dl) (P < 0.001) and 109 IU/ml (range: 33–395 IU/ml)
(P = 0.002), respectively. In patients with symptomatic biliopathy,
median preoperative bilirubin and SAP were 2.0 mg/dl (range:
0.6–5.9 mg/dl) and 134 IU/ml (range: 50–765 IU/ml), respec-
tively; these values decreased postoperatively to 1.3 mg/dl (range:
0.3–5.4 mg/dl) (P < 0.001) and 133 IU/ml (range: 60–395 IU/ml)
(P = 0.290), respectively. In patients with asymptomatic biliopa-
thy, median preoperative bilirubin and SAP levels were 1.7 mg/dl
(range: 0.4–4.0 mg/dl) and 134 IU/ml (range: 23–483 IU/ml),
respectively; these decreased postoperatively to 0.9 mg/dl (range:
0.3–5.2 mg/dl) (P = 0.002) and 92 IU/ml (range: 33–232 IU/ml)
(P = 0.001), respectively. In patients who underwent shunt sur-
gery for PB, median bilirubin decreased postoperatively from
1.8 mg/dl (range: 0.4–5.9 mg/dl) to 1.0 mg/dl (range: 0.3–5.4 mg/
dl) (P < 0.001) andmedian SAP decreased from 150 IU/ml (range:
50–765 IU/ml) to 110 IU/ml (range: 33–395 IU/ml) (P = 0.003).
In patients who underwent splenectomy–devascularization,
median bilirubin decreased postoperatively from 1.9 mg/dl
(range: 0.6–4.0 mg/dl) to 1.2 mg/dl (range: 0.6–5.2 mg/dl) (P =
0.023) and median SAP decreased from 105 IU/ml (range:
23–287 IU/ml) to 98 IU/ml (range: 60–218 IU/ml) (P = 0.27)
(Table 4).
Follow-up
There was no perioperative mortality. Overall, 43 of the 56
(76.8%) patients were followed for a median of 48 months (range:
14–120 months). Thirteen patients were lost to follow-up.
After operation, seven of 43 patients in the study group (includ-
ing the EHPVO and NCPF subgroups) required ERCP with stent-
ing for jaundice and fever. Of these, two patients had
asymptomatic PB prior to shunt surgery and developed symp-
toms secondary to CBD stones at 3 years and 7 years, respectively,
after shunt surgery and cholecystectomy; these patients were
treated with ERCP, stone removal and sphincterotomy. These
patients continue to be symptom-free and have not required any
further endotherapy on follow-up. In the other five patients, the
symptoms of biliopathy continued to require multiple ERCP and
stent placements. One patient had a massive lower GI bleed from
jejunal varices at 10 years after splenectomy–devascularization
and died. Two patients continued to have dominant CBD stricture
postoperatively, which required frequent stent exchange, and sub-
sequently underwent successful Roux-en-Y hepaticojejunostomy
at 16 months and 48 months after shunt surgery, respectively. The
remaining two patients are currently maintained on endoscopic
stents. All four of the patients with persistent jaundice underwent
Doppler ultrasound (US) during follow-up, which revealed patent
shunts in all but one patient, who experienced a rebleed after
Figure 2 Magnetic resonance cholangiopancreatography showing
dilatation of the intrahepatic biliary radicals and dominant common
bile duct compression
Table 3 Procedures performed in portal biliopathy (PB)
Procedure EHPVO-PB NCPF-PB Total
(n = 41), n (n = 15), n (n = 56),
n (%)
Proximal lienorenal shunt 30 7 37 (66.1)
Distal lienorenal shunt 1 0 1 (1.5)
Mesocaval shunt 1 0 1 (1.5)
Lieno-adrenal shunt 1 0 1 (1.5)
Splenectomy with
devascularization
8 8 16 (28.5)
Cholecystectomy with shunt
or splenectomy
6 2 8 (14.3)
Cholecystojejunostomy 1 0 1 (1.5)
Choledochojejunostomy 0 1 1 (1.5)
EHPVO, extrahepatic portal venous obstruction; NCPF, non-cirrhotic
portal fibrosis.
Table 4 Effects of surgery in patients with portal biliopathy (PB)
(n = 56)
Investigations Preoperative
median (range)
Postoperative
median (range)
P-value
Shunt surgery
Bilirubin, mg/dl 1.8 (0.4–5.9) 1.0 (0.3–5.4) <0.001
SAP, IU/ml 150 (50–765) 110 (33–395) 0.003
Non-shunt surgery
Bilirubin, mg/dl 1.9 (0.6–4.0) 1.2 (0.6–5.2) 0.023
SAP, IU/ml 106 (23–287) 98 (60–218) 0.266
SAP, serum alkaline phosphatase.
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6 months of lienorenal shunt. This shunt was shown to have
thrombosed. The patient subsequently underwent a mesocaval
shunt procedure. However, this patient continued to have persis-
tent jaundice with evidence of patent shunt on longterm
follow-up (at 36 months).
Eight of the 43 patients had rebleeding. Of these, two patients
belonged to the group with persistent jaundice. As stated earlier,
one of these patients died and one required a mesocaval shunt as
a result of recurrent bleeding with a blocked shunt. The other six
patients were successfully managed with endotherapy. A total of
38 of 43 patients were found to have returned to work after
surgery, were free from symptoms of biliary obstruction, did not
require frequent hospital visits or endoscopic treatments and were
leading normal lives. Details of follow-up are given in Table 5.
Discussion
Portal biliopathy is most commonly associated with EHPVO. It is
a late and progressive manifestation of the condition10 and may
lead to hepatic dysfunction11 if not treated. Reported incidences
range from 80% to 100%.3,4 However, only 20–30% of patients
with PB have symptoms related to biliary obstruction.12,13 Portal
biliopathy is also seen in patients with cirrhosis of the liver and
NCPF, but its incidence in this context is lower (9–40%).5 In the
current series, incidences of PB were 36.2% and 35.7% in
patients with EHPVO and NCPF, respectively. Incidences of
symptomatic biliopathy were 18.4% in EHPVO and 7% in NCPF,
respectively. This low overall incidence may reflect the fact that
biliary imaging or ERCP were performed in symptomatic
patients only. The median age of patients with EHPVO without
biliopathy was 18 years (range: 4–57 years), whereas the median
age of patients with symptomatic biliopathy was 26 years (range:
13–50 years) (P = 0.005). Similarly, the difference in median age
at presentation between patients with asymptomatic (19 years;
range: 3–32 years) and symptomatic biliopathy was also signifi-
cant (P = 0.034). This corroborates findings of previous studies
indicating that symptomatic PB is a late and progressive mani-
festation of EHPVO, whereas asymptomatic changes may be
present at initial presentation.
Most patients with PB were asymptomatic. Symptoms include
jaundice, pruritus, fever and cholangitis. The incidences range
from 5% to 38%.5,10 In the current study, 24 of 56 (42.9%) patients
were symptomatic. However, even in this group, upper GI bleed-
ing was the chief indication for surgery in 11 of 24 patients.
Symptomatic biliopathy was the chief indication for surgery in 13
patients. Choudhuri et al.6 first described portosystemic shunting
in a patient with CBD obstruction and portal cavernoma associ-
ated with bleeding. The authors found a reversal of the CBD
obstruction after shunt surgery. Chaudhary et al.7 investigated the
results of lienorenal shunt in seven patients with symptomatic
biliopathy and reported a reversal of biliopathy in five patients; the
remaining two patients required bilioenteric bypass at 6 months
postoperatively.
In the current series, the most common surgery performed
involved a proximal lienorenal shunt (66.1%); this was also the
procedure of choice. Splenectomy with gastro-oesophageal devas-
cularization was performed in 28.5% of patients.
Analysis of pre- and postoperative bilirubin and SAP levels in
the study group showed a significant decrease in both in patients
with biliopathy after surgical intervention (including both shunt
and non-shunt surgeries) (P < 0.001 and P = 0.002, respectively).
This supports the suggestion that any surgery that is designed
to reduce portal pressure should also be effective in relieving
biliary obstruction. These decreases in bilirubin and SAP levels
were significant in both symptomatic and asymptomatic PB.
When the study group was divided into patients who under-
went shunt surgery and patients who underwent splenectomy–
devascularization, the decrease in bilirubin remained significant in
both groups (P < 0.001 and P = 0.023, respectively). However, the
decrease in SAP after splenectomy–devascularization was not sig-
nificant (P = 0.27). Khuroo et al.10 reported the results of four
patients with PB and concluded that only shunt surgeries were
effective in reversing biliopathy. Similarly, shunt surgery repre-
sented the preferred operative technique in the current study,
especially in patients in whom PB was the chief indication for
surgery, and splenectomy–devascularization was performed
only in the absence of a viable shuntable vein. However, when
patients who had undergone splenectomy–devascularization were
Table 5 Follow-up in patients with portal biliopathy (PB)
Follow-up, months,
median (range)
EHPVO-PB
(n = 34)
NCPF-PB
(n = 9)
Total (n = 43)
42 (14–120) 36 (14–72)
Shunt (n = 29) Non-shunt (n = 5) Shunt (n = 4) Non-shunt (n = 5)
Jaundice 5 1 0 1 7
ERCP required 5 1 0 1 7
Bilioenteric bypass 2 0 0 0 2
Bleed 3 2 1 2 8
Ascites 0 0 1 2 3
Mortality 0 1 0 0 1
EHPVO, extrahepatic portal venous obstruction; NCPF, non-cirrhotic portal fibrosis; ERCP, endoscopic retrograde cholangiopancreatography.
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reviewed, splenectomy–devascularization was found to be effec-
tive in relieving PB by significantly decreasing bilirubin levels. This
probably reflects the reduction in portal flow caused by splenec-
tomy. This concept has been proven in the context of living donor
liver transplantation, in which splenic artery ligation and splenec-
tomy have been shown to decrease portal flow by 10–60%.14,15
Compression of the bile duct by pericholedochal varices is pos-
tulated to represent the main cause of PB. The extrahepatic bile
duct is surrounded by two venous plexuses: the epicholedochal
(Saint) plexus,16 and the paracholedochal (Petren) plexus.17 Dila-
tation of these veins secondary to portal venous obstruction can
cause compression of the bile duct. However, studies have also
shown that in longterm cavernomatous dilatation, neogenesis and
deposition of fibrous tissue over the bile duct do not revert with
shunt surgery18 and can lead to stricture formation. Bile duct
strictures have also been postulated to be secondary to ischaemic
changes that occur following venous damage at the time of portal
vein thrombosis, leading to vascular injury at the level of arterioles
and capillaries.19 Dhiman et al.20 studied five patients with
EHPVO and bile duct abnormalities and found complete reversal
of bile duct changes on ERCP in only one patient post-shunt
surgery suggestive of an ischaemic or fibrosing pathology in the
others. However, in a study of 19 patients with symptomatic bili-
opathy, Vibert et al.21 noted reversibility of changes in all patients
and concluded that ischaemia was unlikely to be the mechanism
for this.
In the current series, 38 patients were found to be symptom-
free on longterm follow-up and did not require multiple interven-
tions for biliary obstruction. Therefore, in this group of patients,
biliary obstruction probably reflected CBD compression alone,
which was relieved after surgery.
Overall, seven patients in the study group developed jaundice
postoperatively and required ERCP. Of these patients, five had
symptomatic biliopathy (five of 24 patients) and four had under-
gone ERCP with multiple stent insertions preoperatively (with a
median of three and a range of two to five attempts per patient).
One patient died after 10 years of follow-up of a massive lower GI
bleed suggestive of a progression of portal hypertension. One
patient had recurrent upper GI bleed with blockade of the lieno-
renal shunt and underwent mesocaval shunt surgery, but he also
had a preoperative history of recurrent episodes of cholangitis
that required ERCP with stenting. Three of these patients had
documented predominant CBD strictures on preoperative ERCP.
All four patients had patent shunts on Doppler US on longterm
follow-up. Two of these patients continued to have recurrent cho-
langitis postoperatively and required multiple stent changes and
eventually underwent uneventful bilioenteric bypass at 18 months
and 4 years after shunt surgery, respectively. All other patients
remained free of any biliary symptoms. Overall, 38 of 43 patients
resumed work after surgery and were found to be leading near-
normal lives.
These findings indicate that shunt surgeries are effective in
reversing the effects of CBD obstruction in the majority of
patients. Patients who are more likely to respond to shunt surgery
are those with: asymptomatic biliopathy; patent shunts; symp-
tomatic biliopathy in the absence of multiple episodes of ERCP
with stenting for preoperative cholangitis, and the absence of pre-
dominant CBD stricture on preoperative imaging. Symptomatic
biliopathy is also a marker for advanced disease as these patients
were significantly older than patients with asymptomatic biliopa-
thy and had a higher incidence of persistent biliary obstruction
than asymptomatic patients (five of 24 vs. two of 32 patients) in
the current study. Thrombosis of shunts may contribute by
causing the progression of portal hypertension, which, in turn,
causes the compression of the CBD. Frequent ERCP and stent
insertions are associated with recurrent cholangitis, whichmay act
as a stimulus for neogenesis, fibrosis and stricture. In the current
study, four of five patients with persistent biliary obstruction had
a history of multiple ERCP and stent insertion in the preoperative
period. Dominant CBD stricture may indicate an irreversible
change in the CBD as all three patients with preoperative evidence
of dominant stricture in the current study continued to require
biliary decompression after shunt surgery.
Conclusions
Successful portosystemic shunt procedures relieve biliary obstruc-
tion in the majority of patients with PB. However, a small per-
centage of patients may continue to progress and eventually
require a bilioenteric bypass. A history of shunt blockade, recur-
rent cholangitis requiring frequent stent changes preoperatively,
and predominant bile duct stricture on preoperative imaging,may
be associated with failure of resolution of PB. This study also
shows that splenectomy with devascularization may alter the
natural history of PB, probably by decreasing the portal flow, and
thus can be considered a therapeutic procedure in patients
without a shuntable vein.
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